Literature DB >> 12853555

Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS.

Sandra Abi-Nassif1, Eugene J Mark, Robert B Fogel, Robert K Hallisey.   

Abstract

A 49-year-old man with cirrhosis due to hepatitis C virus developed interstitial pneumonitis documented by surgical lung biopsy specimen evaluation after two weekly doses of pegylated interferon-alpha(2)b in combination with ribavirin. He developed ARDS and died after 26 days of hospitalization from multisystem organ failure. This case suggests that interstitial pulmonary disease can occur with pegylated interferon-alpha(2)b therapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12853555     DOI： 10.1378/chest.124.1.406

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


  12 in total

Review 1.  Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C.

Authors:  Fan-Pu Ji; Zheng-Xiao Li; Hong Deng; Hong-An Xue; Yuan Liu; Min Li
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

2.  Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C.

Authors:  Rena Kaneko; Masazumi Ogawa; Tomoyuki Iwata; Yasuyoshi An; Motoki Nakagawa; Satoshi Kusayanagi; Satoshi Kamisago; Tomoyuki Umeda; Yuzuru Sato
Journal:  Clin J Gastroenterol       Date:  2009-05-26

3.  Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report.

Authors:  Ozlen Atug; Hakan Akin; Yesim Ozen Alahdab; Berrin Ceyhan; Nurdan Tozun; Osman Ozdogan
Journal:  Cases J       Date:  2009-03-10

4.  Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C.

Authors:  Sonu Dhillon; Anshul Kaker; Aneil Dosanjh; Deepa Japra; David H Vanthiel
Journal:  Dig Dis Sci       Date:  2010-04-22       Impact factor: 3.199

5.  Expectoration of large bronchial casts secondary to the treatment of chronic hepatitis C with pegylated interferon and ribavirin.

Authors:  Evaldo Stanislau Affonso de Araújo; Aleia Faustina Campos; Juliana Yamashiro; Evandro Sobrosa Mello; Teresa Takagaki; Antonio Alci Barone
Journal:  Clinics (Sao Paulo)       Date:  2010-07       Impact factor: 2.365

Review 6.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

7.  The use of whey protein concentrate in management of chronic hepatitis C virus - a pilot study.

Authors:  Gamal Elattar; Zeinab Saleh; Safinaz El-Shebini; Atif Farrag; Mona Zoheiry; Azza Hassanein; Maged El-Ghannam; Shendy Shendy; Ehab El-Dabaa; Nariman Zahran
Journal:  Arch Med Sci       Date:  2010-10-26       Impact factor: 3.318

8.  Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function.

Authors:  Arturo Cortés-Telles
Journal:  Lung India       Date:  2016 Mar-Apr

9.  Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection.

Authors:  Iram Gull; Muhammad Shahbaz Aslam; Imran Tipu; Roohi Mushtaq; Tehseen Zamir Ali; Muhammad Amin Athar
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

Review 10.  Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Authors:  Serena Slavenburg; Yvonne F Heijdra; Joost P H Drenth
Journal:  Dig Dis Sci       Date:  2009-04-28       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.